New lung cancer cocktail aims to outperform current standard therapy

NCT ID NCT07662811

Not yet recruiting Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study includes about 396 adults whose tumors have a specific marker (PD-L1 ≥1%) and who have not had prior systemic therapy. The goal is to see if the new combination shrinks tumors more effectively and delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYHX2011 (a form of paclitaxel), carboplatin, enlonstobart
What this could lead to: If successful, this combination could offer a more effective first-line treatment option for people with advanced squamous non-small cell lung cancer.
What could go wrong: This is a phase II/III trial, so results are not yet confirmed. The new combination may not prove better than the standard therapy and could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.